Accent Capital Management LLC Sells 19,336 Shares of Kenvue Inc. (NYSE:KVUE)

Accent Capital Management LLC decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 69.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,586 shares of the company’s stock after selling 19,336 shares during the period. Accent Capital Management LLC’s holdings in Kenvue were worth $199,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Riverview Trust Co acquired a new stake in shares of Kenvue in the 3rd quarter valued at $30,000. Ashton Thomas Securities LLC acquired a new stake in Kenvue in the third quarter valued at about $35,000. Studio Investment Management LLC grew its position in Kenvue by 52.1% in the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after acquiring an additional 845 shares during the last quarter. Deseret Mutual Benefit Administrators grew its position in Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after acquiring an additional 651 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Kenvue in the second quarter worth about $61,000. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

Shares of KVUE opened at $23.82 on Friday. The business has a 50-day moving average of $22.77 and a 200-day moving average of $20.69. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market capitalization of $45.67 billion, a price-to-earnings ratio of 43.31, a price-to-earnings-growth ratio of 2.16 and a beta of 1.36. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.13.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same quarter last year, the business earned $0.31 EPS. The company’s revenue was down .4% compared to the same quarter last year. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.44%. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on KVUE shares. JPMorgan Chase & Co. lifted their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research note on Tuesday, September 24th. UBS Group boosted their price objective on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Finally, Piper Sandler increased their target price on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.